## SHARE CAPITAL

The authorised and issued share capital of our Company is as follows:

HK\$

#### Authorised:

5,000,000,000	Shares	50,000,000

Assuming the Over-allotment Option is not exercised, our share capital immediately following the Global Offering and the Capitalisation Issue will be as follows:

#### Shares issued or to be issued, fully paid or credited as fully paid upon completion of the Capitalisation Issue and the Global Offering:

Shares in issue as at the date of this prospectus Shares to be issued pursuant to	1 7.499.999
the Capitalisation Issue	,,
Shares to be issued pursuant to the Global Offering	2,500,000
	10,000,000
	Shares to be issued pursuant to the Capitalisation Issue

Assuming the Over-allotment Option is exercised in full, our Company's share capital immediately following the Global Offering and the Capitalisation Issue will be as follows:

#### Shares issued or to be issued, fully paid or credited as fully paid upon completion of the Capitalisation Issue and the Global Offering:

100	Shares in issue as at the date of this prospectus	1
749,999,900	Shares to be issued pursuant to the Capitalisation Issue	7,499,999
250,000,000 37,500,000	Shares to be issued pursuant to the Global Offering Shares to be issued pursuant to the Over-allotment Option	2,500,000 375,000
1,037,500,000		10,375,000

According to Rule 8.08 of the Listing Rules, at the time of the listing and at all times thereafter, we must maintain the "minimum prescribed percentage" of 25% of our issued share capital in the hands of the public.

#### ASSUMPTIONS

The above tables assume that the Global Offering and the Capitalisation Issue become unconditional and will be completed in accordance with the relevant terms and conditions. It, however, takes no account of any Shares which may fall to be issued pursuant to the exercise of options granted or to be granted under the Share Option Schemes or which may be allotted and issued, or repurchased by our Company pursuant to the issuing mandate and repurchase mandate as described below.

The Offer Shares and the Shares to be issued upon the exercise of the Over-allotment Option, will rank pari passu in all respects with all other Shares in issue or to be issued as mentioned in this prospectus and will rank in full for all dividends or other distributions declared, made or paid on the Shares after the date of this prospectus (other than entitlements under the Capitalisation Issue).

#### SHARE OPTION SCHEMES

We adopted the Pre-IPO Share Option Scheme on 23 June 2010 under which we have conditionally granted options to purchase Shares with an exercise price equal to the Offer Price per Share. An aggregate of 12,140,000 Shares are issuable upon exercise of options granted under the Pre-IPO Share Option Scheme, representing approximately 1.21% of the Shares in issue following completion of the Global Offering and the Capitalisation Issue (assuming no exercise of the Over-allotment Option).

In addition, we conditionally approved the Post-IPO Share Option Scheme on 23 June 2010. Pursuant to the Post-IPO Share Option Scheme, eligible participants of the scheme (including without limitation, our Directors and directors of other members of our Group, full-time and part-time employees, executives, officers, advisors, and any suppliers, customers, consultants, agents and advisers of the Group who, in the sole opinion of our Board of Directors, will contribute or have contributed to our Group) may be granted options which entitle them to subscribe Shares representing (when aggregated with options granted under any other scheme) not more than 10% of the aggregate number of Shares in issue immediately following the completion of the Global Offering and Capitalisation Issue (without taking into account any Shares that may be issued upon the exercise of the Over-allotment Option), representing 100,000,000 Shares.

Additional information regarding the Share Option Schemes is set forth in the sections headed "Statutory and General Information – Further Information about Directors, Substantial Shareholders and Experts – Share Option Schemes" Appendix VI to this prospectus.

#### GENERAL MANDATE TO ISSUE SHARES

The Directors have been granted a general unconditional mandate to exercise all the powers of our Company to allot, issue and deal with the Shares (including the power to make an offer or agreement, or grant securities which would or might require Shares to be allotted and issued) subject to the requirement that the aggregate nominal value of the Shares so allotted and issued or agreed conditionally or unconditionally to be allotted and issued (otherwise than by way of rights issue or pursuant to the exercise of any subscription rights attaching to any warrants which may be allotted and issued by our Company from time to time or pursuant to the exercise of any options granted or to be granted under the Share Option Schemes or an allotment and issue of Shares in lieu of the whole or part of a dividend on Shares in accordance with the Articles of Association), shall not exceed:

- (a) 20% of the aggregate nominal value of the Shares in issue immediately following completion of the Global Offering and the Capitalisation Issue (but excluding any Shares which may fall to be allotted and issued pursuant to the exercise of the Over-allotment Option); and
- (b) the aggregate nominal value of the share capital of our Company repurchased by our Company (if any) under the authority referred to in the paragraph headed "General Mandate to Repurchase Shares" below.

The general mandate to issue Shares will remain in effect until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of our Company;
- (ii) the expiration of the period within which our Company's next annual general meeting is required be held by any applicable law or the Articles of Association; or
- (iii) the time when such mandate is revoked or varied by an ordinary resolution of the Shareholders in a general meeting.

# SHARE CAPITAL

For further details of this general mandate, please refer to the paragraph headed "3. Written Resolutions of the Shareholders" in Appendix VI to this prospectus.

### **GENERAL MANDATE TO REPURCHASE SHARES**

The Directors have been granted a general unconditional mandate to exercise all the powers of our Company to repurchase our own Shares on the Stock Exchange or on any other stock exchange on which the securities of our Company may be listed and which is recognised by the SFC and the Stock Exchange for this purpose, such number of Shares with an aggregate nominal value not exceeding 10% of the aggregate nominal value of the Shares in issue immediately following completion of the Global Offering and the Capitalisation Issue (but excluding any Shares which may fall to be allotted and issued pursuant to the exercise of the Over-allotment Option).

This mandate only relates to purchases made on the Stock Exchange, or on any other stock exchange on which the Shares are listed (and which is recognised by the SFC and the Stock Exchange for this purpose), and made in accordance with all applicable laws and requirements of the Listing Rules. An explanatory statement related to the general mandate to repurchase Shares is set out in the section headed "Repurchase of our own securities" in Appendix VI to this prospectus.

The general mandate to repurchase Shares will remain in effect until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of our Company;
- (ii) the expiration of the period within which our Company's next annual general meeting is required be held by any applicable law or the Articles of Association; or
- (iii) the time when such mandate is revoked or varied by an ordinary resolution of the Shareholders in a general meeting.

For further details of this general mandate, please refer to the paragraph headed "3. Written Resolutions of the Shareholders" in Appendix VI to this prospectus.